Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Change in Accured Expenses (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Change in Accured Expenses for 13 consecutive years, with $3.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses rose 391.95% to $3.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.3 million, a 241.21% increase, with the full-year FY2024 number at $1.5 million, up 120.69% from a year prior.
  • Change in Accured Expenses was $3.6 million for Q3 2025 at Theravance Biopharma, up from $3.2 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $9.9 million in Q3 2022 to a low of -$17.3 million in Q1 2021.
  • A 5-year average of -$2.2 million and a median of -$791000.0 in 2022 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: plummeted 63.99% in 2021, then surged 391.95% in 2025.
  • Theravance Biopharma's Change in Accured Expenses stood at -$17.3 million in 2021, then rose by 25.78% to -$12.8 million in 2022, then skyrocketed by 66.22% to -$4.3 million in 2023, then soared by 168.96% to $3.0 million in 2024, then grew by 20.56% to $3.6 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Change in Accured Expenses are $3.6 million (Q3 2025), $3.2 million (Q2 2025), and -$1.5 million (Q1 2025).